<?xml version='1.0' encoding='utf-8'?>
<document id="25424014"><sentence text="Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers."><entity charOffset="66-79" id="DDI-PubMed.25424014.s1.e0" text="canagliflozin" /><entity charOffset="84-97" id="DDI-PubMed.25424014.s1.e1" text="teneligliptin" /><pair ddi="false" e1="DDI-PubMed.25424014.s1.e0" e2="DDI-PubMed.25424014.s1.e0" /><pair ddi="false" e1="DDI-PubMed.25424014.s1.e0" e2="DDI-PubMed.25424014.s1.e1" /></sentence><sentence text="To investigate the pharmacokinetic/pharmacodynamic interactions of the antidiabetic agents canagliflozin (a sodium-glucose cotransporter-2 inhibitor) and teneligliptin (a dipeptidyl peptidase-4 inhibitor) in Japanese healthy adult men"><entity charOffset="91-104" id="DDI-PubMed.25424014.s2.e0" text="canagliflozin" /><entity charOffset="154-167" id="DDI-PubMed.25424014.s2.e1" text="teneligliptin" /><pair ddi="false" e1="DDI-PubMed.25424014.s2.e0" e2="DDI-PubMed.25424014.s2.e0" /><pair ddi="false" e1="DDI-PubMed.25424014.s2.e0" e2="DDI-PubMed.25424014.s2.e1" /></sentence><sentence text="" /><sentence text="Open-label, one-way crossover study used canagliflozin (200 mg/day p"><entity charOffset="41-54" id="DDI-PubMed.25424014.s4.e0" text="canagliflozin" /></sentence><sentence text="o" /><sentence text=") and teneligliptin (40mg/day p"><entity charOffset="6-19" id="DDI-PubMed.25424014.s6.e0" text="teneligliptin" /></sentence><sentence text="o)" /><sentence text=" A single dose of object drug (either canagliflozin or teneligliptin) was administered on day 1 followed by washout and continuous administration of precipitant drug (days 1 - 9)"><entity charOffset="38-51" id="DDI-PubMed.25424014.s8.e0" text="canagliflozin" /><entity charOffset="55-68" id="DDI-PubMed.25424014.s8.e1" text="teneligliptin" /><pair ddi="false" e1="DDI-PubMed.25424014.s8.e0" e2="DDI-PubMed.25424014.s8.e0" /><pair ddi="false" e1="DDI-PubMed.25424014.s8.e0" e2="DDI-PubMed.25424014.s8.e1" /></sentence><sentence text=" Both drugs were concomitantly administered on day 7" /><sentence text="" /><sentence text="No changes in AUC0 - 72h and Cmax were observed for canagliflozin+teneligliptin versus monotherapy; geometric mean ratios for AUC0 - 72h and Cmax were 0"><entity charOffset="52-79" id="DDI-PubMed.25424014.s11.e0" text="canagliflozin+teneligliptin" /></sentence><sentence text="982 and 0" /><sentence text="982 for the plasma concentration of canagliflozin and 0"><entity charOffset="36-49" id="DDI-PubMed.25424014.s13.e0" text="canagliflozin" /></sentence><sentence text="983 and 0" /><sentence text="976 for the plasma concentration of teneligliptin, respectively"><entity charOffset="36-49" id="DDI-PubMed.25424014.s15.e0" text="teneligliptin" /></sentence><sentence text=" Plasma concentrations of active and total glucagon-like peptide-1 (GLP-1) increased with canagliflozin+teneligliptin versus teneligliptin alone"><entity charOffset="90-117" id="DDI-PubMed.25424014.s16.e0" text="canagliflozin+teneligliptin" /></sentence><sentence text=" Mean AUC0" /><sentence text="5 - 4h increased post-meal, on combination therapy, from 9" /><sentence text="6 to 12" /><sentence text="5 pmol·h/l (active GLP-1) and from 21" /><sentence text="5 to 32" /><sentence text="3 pmol·h/l (total GLP-1)" /><sentence text=" Adverse events developed in four subjects; all were mild and resolved but one subject withdrew due to generalized erythema" /><sentence text="" /><sentence text="GLP-1 levels increased with the canagliflozin+teneligliptin combination, and no PK interaction was observed"><entity charOffset="32-59" id="DDI-PubMed.25424014.s25.e0" text="canagliflozin+teneligliptin" /></sentence><sentence text=" This combination may show favorable antidiabetic effects without increasing systemic exposure" /><sentence text="" /></document>